Targeted delivery of microRNA 146b mimic to hepatocytes by lactosylated PDMAEMA nanoparticles for the treatment of NAFLD
Source abstract
Abstract
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide, and precision therapeutic will be a benefit for the NAFLD regression. In this study, we observed low microRNA 146 b (miR-146 b) expression in NAFLD mice model induced by methionine–choline-deficient diet (MCD) compared with control group. Furthermore, miR-146b−/− mice induced MCD exhibited severe liver steatosis and hepatitis. A bio-distribution study showed that novel Lactosylated PDMAEMA nanoparticles effectively targeted hepatocytes Lac-PDMAEMA. We coupled miR-146b mimic with Lac-PDMAEMA and then were administrated to NAFLD mice model, which could obviously alleviate the hepatic steatosis. Lac-PDMAEMA effectively delivered miR-146b mimic to hepatocytes with a ∼8-fold upregulation of miR-146b mimic targeting MyD88 and IRAK1, and in turn suppressed the expression of PPARγ. Meanwhile, TNF-α and IL-6 mRNA levels were decreased after administration of Lac-PDMAEMA/miR-146b mimic. So, we made a conclusion that targeted delivering miR-146b mimic to the hepatocytes by, coupling Lac-PDMAEMA nanoparticles could effectively alleviate the hepatic steatosis in NAFLD mice, which maybe bring a new and effective way to intervene and therapy the NAFLD.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Liver Disease Diagnosis and Treatment · MicroRNA in disease regulation · Circular RNAs in diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China;
Nanfang Hospital, Southern Medical University, Guangzhou, China;
Department of Gastroenterology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China
Funding
International Science and Technology Cooperation Program of China · National Natural Science Foundation of China
References (47)
Show source-provided references
1. 10.1002/hep.2843110.1002/hep.28431 ↗
2. 10.1038/nrgastro.2013.14910.1038/nrgastro.2013.149 ↗
3. 10.1038/nm.433410.1038/nm.4334 ↗
4. 10.1002/hep.2895310.1002/hep.28953 ↗
5. 10.1016/j.jhep.2016.08.02410.1016/j.jhep.2016.08.024 ↗
6. 10.1053/j.gastro.2017.02.01610.1053/j.gastro.2017.02.016 ↗
7. Non-alcoholic fatty liver disease: assessment and management · 2016
8. 10.1002/hep.2455210.1002/hep.24552 ↗
9. 10.1016/j.jhep.2007.04.01910.1016/j.jhep.2007.04.019 ↗
10. 10.1002/hep.2312210.1002/hep.23122 ↗
11. 10.1038/nature0287110.1038/nature02871 ↗
12. 10.1093/eurheartj/ehw14610.1093/eurheartj/ehw146 ↗
13. 10.1038/nrm331310.1038/nrm3313 ↗
14. 10.1073/pnas.121985211010.1073/pnas.1219852110 ↗
15. 10.1016/j.ebiom.2016.10.04110.1016/j.ebiom.2016.10.041 ↗
16. 10.1073/pnas.060529810310.1073/pnas.0605298103 ↗
17. 10.1111/liv.1267410.1111/liv.12674 ↗
18. 10.1371/journal.pone.003279410.1371/journal.pone.0032794 ↗
19. 10.1016/j.biomaterials.2014.02.00610.1016/j.biomaterials.2014.02.006 ↗
20. 10.7150/thno.1313010.7150/thno.13130 ↗
21. 10.1038/mt.2010.13610.1038/mt.2010.136 ↗
22. 10.1016/j.biomaterials.2006.11.01010.1016/j.biomaterials.2006.11.010 ↗
23. 10.1016/j.bbamem.2007.05.01110.1016/j.bbamem.2007.05.011 ↗
24. 10.1016/j.jconrel.2013.03.02010.1016/j.jconrel.2013.03.020 ↗
25. Zhou X · Int J Nanomedicine · 2012 · 7 · 5465
26. 10.1111/jgh.1287810.1111/jgh.12878 ↗
27. 10.1126/scitranslmed.aaa565710.1126/scitranslmed.aaa5657 ↗
28. 10.1002/hep.2896210.1002/hep.28962 ↗
29. 10.1038/nature1696910.1038/nature16969 ↗
30. 10.1016/j.jhep.2009.10.00210.1016/j.jhep.2009.10.002 ↗
31. 10.1152/ajpgi.00002.200410.1152/ajpgi.00002.2004 ↗
32. 10.1016/S0016-5085(96)70028-810.1016/S0016-5085(96)70028-8 ↗
33. 10.1002/hep.2070110.1002/hep.20701 ↗
34. 10.1016/S1097-2765(00)80211-710.1016/S1097-2765(00)80211-7 ↗
35. 10.1007/978-3-319-48382-5_1910.1007/978-3-319-48382-5_19 ↗
36. 10.3390/children406004610.3390/children4060046 ↗
37. 10.1002/hep.2310010.1002/hep.23100 ↗
38. 10.1098/rsif.2009.044310.1098/rsif.2009.0443 ↗
39. 10.1016/j.pneurobio.2016.11.00310.1016/j.pneurobio.2016.11.003 ↗
40. 10.7150/jca.1696110.7150/jca.16961 ↗
41. 10.18632/oncotarget.1564010.18632/oncotarget.15640 ↗
42. 10.1038/s41598-017-06137-810.1038/s41598-017-06137-8 ↗
43. 10.18632/aging.10004210.18632/aging.100042 ↗
44. 10.1016/j.jcmgh.2015.01.00610.1016/j.jcmgh.2015.01.006 ↗
45. 10.1371/journal.pone.017421810.1371/journal.pone.0174218 ↗
46. 10.3109/07853890.2013.77033310.3109/07853890.2013.770333 ↗
47. 10.1016/j.immuni.2008.08.01210.1016/j.immuni.2008.08.012 ↗